Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
Advertisement
Articles by Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
Advertisement
Latest Updated Articles
Optimizing Treatment Selection for Patients with FLT3-ITD AMLPublished: July 24th 2023 | Updated:
Using MRD to Monitor Therapeutic Response in ALLPublished: June 30th 2021 | Updated:
- Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML
Published: July 17th 2023 | Updated:
- An Introduction to Biomarker Testing in Acute Myeloid Leukemia
Published: June 26th 2023 | Updated:
The Evolving Treatment Landscape for ALLPublished: June 30th 2021 | Updated:
- Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia
Published: July 17th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5